Hikma Pharmaceuticals Forecast, price target & analysts
Hikma Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Hikma Pharmaceuticals Classifications & Recommendation:
Hikma Pharmaceuticals Price Target
| Target Price | GBP24.34 |
| Price | GBP21.82 |
| Potential |
11.56%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Hikma Pharmaceuticals 2026 .
The average Hikma Pharmaceuticals target price is GBP24.34.
This is
11.56%
register free of charge
GBP31.06
42.34%
register free of charge
GBP20.04
8.17%
register free of charge
|
|
| A rating was issued by 11 analysts: 7 Analysts recommend Hikma Pharmaceuticals to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Hikma Pharmaceuticals stock has an average upside potential 2026 of
11.56%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion GBP | 2.45 | 2.55 |
| 5.81% | 4.24% | |
| EBITDA Margin | 24.85% | 26.88% |
| 4.75% | 8.18% | |
| Net Margin | 11.52% | 14.38% |
| 73.96% | 24.88% |
9 Analysts have issued a sales forecast Hikma Pharmaceuticals 2025 . The average Hikma Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Hikma Pharmaceuticals EBITDA forecast 2025. The average Hikma Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Hikma Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Hikma Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share GBP | 1.27 | 1.65 |
| 84.06% | 29.92% | |
| P/E | 1,320.34 | |
| EV/Sales | 2.25 |
6 Analysts have issued a Hikma Pharmaceuticals forecast for earnings per share. The average Hikma Pharmaceuticals <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Hikma Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Hikma Pharmaceuticals...
Current Hikma Pharmaceuticals Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Berenberg Bank | Locked ➜ Locked | Locked | Jan 29 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Berenberg Bank: Locked ➜ Locked
|
Jan 29 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
